CA2798101A1 - Processes for preparing linezolid - Google Patents

Processes for preparing linezolid Download PDF

Info

Publication number
CA2798101A1
CA2798101A1 CA2798101A CA2798101A CA2798101A1 CA 2798101 A1 CA2798101 A1 CA 2798101A1 CA 2798101 A CA2798101 A CA 2798101A CA 2798101 A CA2798101 A CA 2798101A CA 2798101 A1 CA2798101 A1 CA 2798101A1
Authority
CA
Canada
Prior art keywords
fluoro
mixing
salt
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2798101A
Other languages
English (en)
French (fr)
Inventor
James R. Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA2798101A1 publication Critical patent/CA2798101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2798101A 2010-04-30 2011-04-28 Processes for preparing linezolid Abandoned CA2798101A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US32989210P 2010-04-30 2010-04-30
US61/329,892 2010-04-30
US35985110P 2010-06-30 2010-06-30
US61/359,851 2010-06-30
US37557610P 2010-08-20 2010-08-20
US61/375,576 2010-08-20
US38953410P 2010-10-04 2010-10-04
US61/389,534 2010-10-04
US42144210P 2010-12-09 2010-12-09
US61/421,442 2010-12-09
PCT/US2011/034278 WO2011137222A1 (en) 2010-04-30 2011-04-28 Processes for preparing linezolid

Publications (1)

Publication Number Publication Date
CA2798101A1 true CA2798101A1 (en) 2011-11-03

Family

ID=44861911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798101A Abandoned CA2798101A1 (en) 2010-04-30 2011-04-28 Processes for preparing linezolid

Country Status (15)

Country Link
US (2) US9206141B2 (https=)
EP (2) EP2563781B1 (https=)
JP (1) JP5865898B2 (https=)
KR (1) KR20130108975A (https=)
CN (1) CN103025730A (https=)
AU (1) AU2011245302A1 (https=)
BR (1) BR112012027901A2 (https=)
CA (1) CA2798101A1 (https=)
IL (1) IL222770A0 (https=)
MX (1) MX2012012627A (https=)
RU (1) RU2012151303A (https=)
SG (1) SG185103A1 (https=)
TW (1) TWI535715B (https=)
WO (1) WO2011137222A1 (https=)
ZA (1) ZA201208382B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5865898B2 (ja) * 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation リネゾリドを調製するためのプロセス
CN106279054A (zh) 2011-02-24 2017-01-04 李药业有限公司 利奈唑胺及其新中间体的新制备方法
WO2013072923A1 (en) * 2011-09-19 2013-05-23 Cadila Healthcare Limited Process for the preparation of crystalline linezolid
CN103254148B (zh) 2012-02-15 2016-04-13 浙江海正药业股份有限公司 利奈唑胺中间体的制备方法
CN103288814B (zh) * 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
US9562040B2 (en) 2012-04-06 2017-02-07 Indiana University Research And Technology Corporation Processes for preparing Rivaroxaban
ITMI20120655A1 (it) * 2012-04-19 2013-10-20 Bioindustria Lab Italiano M Edicinali Spa Procedimento per la preparazione di linezolid
AR090844A1 (es) * 2012-04-27 2014-12-10 Actelion Pharmaceuticals Ltd Proceso para elaborar derivados de naftiridina
CN103626712B (zh) * 2012-08-23 2016-06-01 重庆药友制药有限责任公司 一种用于制备利奈唑胺的中间体及其制备方法
WO2014045292A1 (en) * 2012-09-20 2014-03-27 Symed Labs Limited Improved process for the preparation of linezolid intermediate
WO2014170908A1 (en) * 2013-04-18 2014-10-23 Nosch Labs Private Limited Process for preparation of oxazolidinone derivatives
EP3250568A4 (en) * 2016-04-21 2018-08-01 Optimus Drugs Pvt Ltd An improved process for the preparation of linezolid
CN110194750A (zh) * 2019-06-19 2019-09-03 四川美大康华康药业有限公司 一种利奈唑胺的制备方法及精制方法
CN112159368A (zh) * 2020-07-07 2021-01-01 杭州杜易科技有限公司 一种利奈唑胺中间体的合成方法
RU2760198C1 (ru) * 2020-12-16 2021-11-22 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Однореакторный способ получения полупродукта для синтеза линезолида
CN115684399B (zh) * 2022-10-27 2024-12-20 贵州健安德科技有限公司 一种氯醇亚胺的高效液相检测及含量测定方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725450A (en) * 1970-10-05 1973-04-03 Gen Mills Chem Inc Process for the preparation of isocyanates from acyl azides
US4937331A (en) 1988-03-25 1990-06-26 President And Fellows Of Harvard College Chiral azetidinone epoxides
DE4119611A1 (de) * 1991-06-14 1992-12-17 Bayer Ag Mittel zur bekaempfung von schaedlingen auf basis substituierter oxazolidinone, neue substituierte oxazolidinone, deren herstellung und verwendung
TW380137B (en) * 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
DE19542148A1 (de) 1995-11-11 1997-05-15 Hoechst Ag Verfahren zur Herstellung von fluorierten Aromaten
DK1028940T3 (da) 1997-11-07 2007-07-30 Pharmacia & Upjohn Co Llc Fremgangsmåde til fremstilling af oxazolidinoner
US6921825B2 (en) 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
AR027261A1 (es) 2000-02-02 2003-03-19 Upjohn Co Linezolid forma cristalina ii
SE0001866D0 (sv) * 2000-05-18 2000-05-18 Astrazeneca Ab A new process
DE60118241T2 (de) 2000-10-17 2006-12-28 Pharmacia & Upjohn Co. Llc, Kalamazoo Verfahren zur herstellung von oxazolidinonverbindungen
AU2002310156A1 (en) 2001-06-05 2002-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
EP1866295A2 (en) 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Processes for the preparation of linezolid intermediate
KR20080032186A (ko) 2005-07-15 2008-04-14 시클릭스 코포레이션 열가소성 물질에 대한 운반체 및/또는 유동성 개선첨가제로서의 거대고리 폴리에스테르 올리고머
EP2007740A1 (en) 2006-04-07 2008-12-31 Pfizer Products Incorporated Process for preparing linezolid
CN101220001A (zh) 2008-01-25 2008-07-16 浙江博泰化工有限公司 一种利奈唑酮的合成方法
CN101638392B (zh) 2009-08-24 2012-05-16 浙江工业大学 一种列奈唑酮的制备方法
JP5865898B2 (ja) * 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation リネゾリドを調製するためのプロセス

Also Published As

Publication number Publication date
EP2563781B1 (en) 2016-10-26
MX2012012627A (es) 2013-05-09
EP2563781A4 (en) 2013-11-06
US20160024032A1 (en) 2016-01-28
RU2012151303A (ru) 2014-06-10
ZA201208382B (en) 2015-06-24
TWI535715B (zh) 2016-06-01
EP2899185A1 (en) 2015-07-29
IL222770A0 (en) 2012-12-31
BR112012027901A2 (pt) 2015-09-08
EP2563781A1 (en) 2013-03-06
US9206141B2 (en) 2015-12-08
JP2013525454A (ja) 2013-06-20
EP2899185B1 (en) 2018-01-31
US20130053557A1 (en) 2013-02-28
JP5865898B2 (ja) 2016-02-17
KR20130108975A (ko) 2013-10-07
WO2011137222A1 (en) 2011-11-03
US9656973B2 (en) 2017-05-23
TW201144301A (en) 2011-12-16
CN103025730A (zh) 2013-04-03
AU2011245302A1 (en) 2012-11-22
SG185103A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
CA2798101A1 (en) Processes for preparing linezolid
JP2013525454A5 (https=)
NZ610746A (en) Methods of treatment using selective bcl-2 inhibitors
CY1115684T1 (el) Μυκητοκτονα μειγματα που περιεχουν υποκατεστημενα ανιλιδια 1-μεθυλοπυραζολ-4-υλοκαρβονικου οξεος
MX2022014444A (es) Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
PE20171242A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
PE20030607A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
JP2019501948A5 (https=)
ES2559238T3 (es) Agente para reducir el peso de la grasa visceral
BRPI0702299A (pt) composição microbicida, e, método para preparar uma composição microbicida
CL2011002234A1 (es) Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas.
Hafeez et al. Recent progress in the synthesis of diclofenac based NSAIDs analogs/derivatives
RU2019128534A (ru) Химические соединения для лечения туберкулеза
WO2004067480A3 (en) Substituted phenylurea derivatives as hdac inhibitors
DE602004020663D1 (de) Immuntherapeutikum für die kombinierte behandlung von tuberkulose mit anderen pharmazeutika
EP1872780A3 (en) Omega-Phenyloctanamides as therapeutic compounds
Taha et al. Correction to design, synthesis, and biological evaluation of tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors
ATE20346T1 (de) N-(2-(4-hydroxy-3-methoxy-phenyl)-2-hydroxyethyl)3-amino-1-(1-benzimidazolyl)-butan und salze und hydrate mit beta-adrenergischer aktivitaet, therapeutische anwendungen und verfahren zu deren herstellung.
TW200730512A (en) Novel compounds
BR112012008332A2 (pt) processo para preparação de cinacalcet
JP2004509063A5 (https=)
CA2477714A1 (en) New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
EA201201286A1 (ru) Новое биологически активное соединение n-[3-(нитрофениламино)индол-2-илметилен]аминогуанидина гидрохлорид с противовоспалительной активностью

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150428